Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: The intratumoral heterogeneous vascular permeability and cell density of gliomas are associated with IDH mutation status. Therefore, the authors aimed to construct vascular-cellular habitats based on MRI to investigate their correlation with IDH status.

Methods: In this retrospective analysis, 165 patients with pathologically confirmed glioma who underwent preoperative contrast-enhanced T1-weighted imaging and diffusion-weighted imaging (DWI) at three hospitals were included. Four spatial habitats (subregions) based on contrast-enhanced T1-weighted and DWI-derived apparent diffusion coefficient (ADC) images were defined using K-means voxel-wise clustering. The sensitive habitat of IDH mutation was identified and radiomic features were extracted and screened from the whole tumor and the four habitats. Logistic regression classifiers were used to construct predictive models for IDH mutation.

Results: Of the included patients, 109 (mean age 50.78 years) were assigned to the training set and 56 (mean age 48.21 years) to the external test set. The high contrast enhancement (CE)-high ADC subregion was determined as the sensitive habitat. The four habitats model achieved an area under the receiver operating characteristic curve (AUC) of 0.716 (95% CI 0.553-0.879) in the external test set, indicating better performance than that of the traditional whole tumor model (AUC 0.619, 95% CI 0.446-0.792). Model performance was further improved when focusing on the sensitive habitat, for which the external test set AUC was 0.817 (95% CI 0.676-0.958).

Conclusions: MRI habitat analysis based on contrast-enhanced T1-weighted and DWI sequences had high prediction capabilities for glioma IDH mutation status, which could be used to refine individualized treatment regimens for patients with glioma.

Download full-text PDF

Source
http://dx.doi.org/10.3171/2025.5.FOCUS25135DOI Listing

Publication Analysis

Top Keywords

idh mutation
12
contrast-enhanced t1-weighted
12
sensitive habitat
12
external test
12
test set
12
mutation status
8
based contrast-enhanced
8
idh
6
mri-based habitat
4
habitat radiomics
4

Similar Publications

Glioblastoma (GB), IDH-wildtype (IDH-wt), is the most prevalent primary malignant brain neoplasm in adults. Despite adjuvant therapy, the prognosis for these tumors remains dismal, with a median survival of around 15-18 months. Although rare, extracranial metastases from GB are reported with increasing frequency, likely due to advancements in follow-up, treatments, and improved patient survival.

View Article and Find Full Text PDF

On August 6, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to vorasidenib (VORANIGO, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or 2 (IDH1 or IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.

View Article and Find Full Text PDF

Background: Therapies for diffuse glioma induce DNA damage response (DDR), and strategies to exploit DDR defects are active areas of investigation. While global DNA methylation profiling effectively classifies gliomas into subtypes, the epigenetic and gene expression patterns of DDR genes, and their contribution to tumor classification and outcomes, have yet to be fully elucidated. Thus, dissecting the DDR epigenetics, gene expression, and single-cell heterogeneity may reveal key molecular characteristics, refine prognosis, and identify novel treatment strategies and resistance mechanisms.

View Article and Find Full Text PDF

Advanced MRI, Radiomics and Radiogenomics in Unravelling Incidental Glioma Grading and Genetic Status: Where Are We?

Medicina (Kaunas)

August 2025

Neuroradiology Unit, NESMOS (Neuroscience, Mental Health and Sensory Organs) Department, Sant'Andrea Hospital, La Sapienza University, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.

The 2021 WHO classification of brain tumours revolutionised the oncological field by emphasising the role of molecular, genetic and pathogenetic advances in classifying brain tumours. In this context, incidental gliomas have been increasingly identified due to the widespread performance of standard and advanced MRI sequences and represent a diagnostic and therapeutic challenge. The impactful decision to perform a surgical procedure deeply relies on the non-invasive identification of features or parameters that may correlate with brain tumour genetic profile and grading.

View Article and Find Full Text PDF

MYCN amplification defines an aggressive phenotype in IDH-mutant gliomas.

J Pathol Clin Res

September 2025

Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China.

In alignment with the latest WHO classification system, which underscores the integration of molecular alterations in glioma diagnosis and grading, this study investigates the prognostic significance of MYCN amplification in IDH-mutant gliomas, a relationship that remains poorly characterized despite its established association with adverse outcomes in various malignancies. A cohort of 190 patients with IDH-mutant gliomas was analyzed for clinical and pathological characteristics. MYCN amplification status was determined using fluorescence in situ hybridization (FISH) with an MYCN-specific probe.

View Article and Find Full Text PDF